FGADX
Price
$49.26
Change
+$1.67 (+3.51%)
Updated
Jun 12 closing price
Net Assets
3.06B
FKRCX
Price
$44.35
Change
+$1.50 (+3.50%)
Updated
Jun 12 closing price
Net Assets
3.06B
Interact to see
Advertisement

FGADX vs FKRCX

Header iconFGADX vs FKRCX Comparison
Open Charts FGADX vs FKRCXBanner chart's image
FGADX vs FKRCX Comparison Chart in %
View a ticker or compare two or three
VS
FGADX vs. FKRCX commentary
Jun 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGADX is a Buy and FKRCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FGADX (3.06B) and FKRCX (3.06B) have equal amount of cash in the bank . FKRCX pays higher dividends than FGADX: FKRCX (9.93) vs FGADX (9.06). FGADX was incepted earlier than FKRCX: FGADX (29 years) vs FKRCX (57 years). FKRCX (0.87) is less costly to investors than FGADX (0.62). FGADX (22.76) and FKRCX (22.76) have comparable annual turnover. FGADX has a lower initial minimum investment than FKRCX: FGADX (0) vs FKRCX (1000). FGADX (64.74) and FKRCX (64.40) have marching annual gain over last year. FGADX (142.10) and FKRCX (139.14) have equivalent 5 years return.
FGADXFKRCXFGADX / FKRCX
Total Expense Ratio0.620.8771%
Annual Report Gross Expense Ratio0.620.8771%
Fund Existence29 years57 years-
Gain YTD-3.770-3.87997%
Front LoadN/A6%-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets3.06B3.06B100%
Annual Yield % from dividends9.069.9391%
Returns for 1 year64.7464.40101%
Returns for 3 years237.33234.81101%
Returns for 5 years142.10139.14102%
Returns for 10 years291.42282.33103%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SNDX18.250.34
+1.90%
Syndax Pharmaceuticals
BLUW10.31N/A
N/A
Blue Water Acquisition Corp III
BLRKU10.07N/A
N/A
Bluerock Acquisition Corp
QGEN37.06-0.36
-0.96%
Qiagen NV
PIII12.23-1.33
-9.77%
P3 Health Partners Inc